December 21, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
Company
News Sectors
Automotive
Communications
Consumers
CSR
Electronics
Energy
Environment
Financial
Health & Med
Industrial
IT & Internet
Materials
Real Estate
Science & Research
Telecoms
Trade
Transportation
Departments
Annual Reports
Companies
News Alerts
News Search
Photo Gallery
Client Login
Japan Corporate News Network
About JCN
Privacy Policy
RSS  
Terms of Use
 
 
 

 Headline News

Otsuka: U.S. FDA Approves Labeling Update of Abilify Maintena (Aripiprazole) (Dec 8, 2014)
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced that the U.S. Food and Drug Administration (FDA) approved the labeling update of Abilify Maintena (aripiprazole) for extended-release injectable suspension. more info >>
Otsuka Pharmaceutical to Launch L-Cartin FF Tablets for Carnitine Deficiencies in Japan (Dec 1, 2014)
On December 5, Otsuka Pharmaceutical is launching a new form of L-Cartin, L-Cartin Free Form (FF) tablets (generic name levocarnatine) in two doses, 100mg and 250mg. more info >>
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Nitto Denko Corporation (Nitto) announced the initiation of a phase-1b clinical study in the US started in September 2014, to administer a new anti-fibrosis drug in patients for the assessment of safety and efficacy. more info >>
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Mitsui & Co. has invested in "KIFMEC specific purpose company" which has been established in order to lease a hospital building to Kobe International Frontier Medical Center ("KIFMEC"). more info >>
ACN Newswire
 Press Release News

Eisai Listed for 13th Consecutive Year in FTSE4GOOD Index Series, an Index for Socially Responsible Investment (Dec 17, 2014)
Eisai Co., Ltd. announced today that it has been listed for the 13th consecutive year since 2002 in the FTSE4Good Index Series, a global index for socially responsible investment. more info >>
Eisai Demonstrates Efficacy of Investigational Dual Orexin Receptor Antagonist E2006 in Sleep Initiation and Maintenance Data from Phase II Clinical Trial for Insomnia (Dec 10, 2014)
Eisai Co., Ltd. announced today that it has presented data from a Phase II clinical study (Study 201) on its in-house-developed investigational dual orexin receptor antagonist (DORA) E2006 in patients with insomnia disorder at the 53rd American College of Neuropsychopharmacology (ACNP) Annual Meeting held from December 7 through 11, 2014, in Phoenix, Arizona in the United States. more info >>
Eisai Presents Results from Phase III Trial of Antiepileptic Drug Fycompa as Adjunctive Therapy for Primary Generalized Tonic-Clonic Seizures (Dec 9, 2014)
Eisai Co., Ltd. announced today that it has presented the results from a Phase III clinical study (Study 332) of its in-house developed antiepileptic drug (AED) Fycompa (perampanel) in patients with primary generalized tonic-clonic (PGTC) seizures, one of the most severe forms of generalized seizures. more info >>
Eisai to Present New Research on Halaven (Eribulin) at 37th Annual San Antonio Breast Cancer Symposium (Dec 2, 2014)
Eisai Co., Ltd. announced today that new clinical study results on the company's novel anticancer agent Halaven (eribulin mesylate) will be presented during the 37th San Antonio Breast Cancer Symposium (SABCS). more info >>
Eisai Establishes Holding Company Eisai China Holdings Ltd. in China (Dec 1, 2014)
Eisai Co., Ltd. announced today that it has established a holding company Eisai China Holdings Ltd. in Suzhou, Jiangsu Province, China. Eisai China Holdings Ltd. is a subsidiary of Eisai Asia Regional Services Pte. Ltd. which is Eisai's representative subsidiary for Asia located in Singapore. more info >>
 Global Press Release

A*STAR Scientists Discover Gene Critical for Proper Brain Development (Dec 19, 2014)

Eisai Listed for 13th Consecutive Year in FTSE4GOOD Index Series, an Index for Socially Responsible Investment (Dec 17, 2014)

Anti-Diabetic Drug Springs New Hope for Tuberculosis Patients (Dec 17, 2014)

Eisai Demonstrates Efficacy of Investigational Dual Orexin Receptor Antagonist E2006 in Sleep Initiation and Maintenance Data from Phase II Clinical Trial for Insomnia (Dec 10, 2014)

Eisai Presents Results from Phase III Trial of Antiepileptic Drug Fycompa as Adjunctive Therapy for Primary Generalized Tonic-Clonic Seizures (Dec 9, 2014)

JCN Network - Company Profiles - Company Listing
 
CSR Report Download
Most Popular
About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)